NIDDK

Ayaka Sugiura and Jeff Rathmell, PhD, are studying a metabolic enzyme involved in T cell function that may offer a new target for anti-inflammatory therapeutics.

CRISPR screen identifies new anti-inflammatory drug target

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.

Insulin in vials

New way to bEET insulin resistance

Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

Roy Zent, MBBCh, PhD, left, Fabian Bock, MD, PhD, and colleagues are studying the factors involved in the maintenance and integrity of the kidney collecting duct.

Harrison Society researcher discovers key regulator of kidney cell structure

New research from Vanderbilt could aid efforts to promote kidney regeneration after injury or to develop engineered organs.

Pancreatic beta-cell booster

Blocking inflammatory signaling improves beta-cell characteristics in a mouse model of type 2 diabetes and may provide added benefits to GLP-1R diabetes medications.

Stomach

New marker for metaplasia

A protein that transports water, called aquaporin 5, is expressed by cells undergoing changes that may increase risk for gastric cancer development, Vanderbilt researchers discovered.

Molecular imaging of C. diff infection

C. difficile — the leading cause of hospital-associated intestinal infections — induces a rapid influx of bile acids into the gut, which could provide a novel target for blocking infection.

1 2 3 4 5 6 24